Results of a Clinical Multicentric Randomized Phase-Ii Study of Nonsmall Cell Lung-Cancer Treated With Vinorelbine Cisplatin Versus Vinorelbine Alone

Lorusso,; Pezzella, G.; Catino, A.; Guida, Michele; Scoditti, S; Lorenzo, R.; Toma, P; Dellatommasa, S; Bisconti, Mario; Mastria, A; Durini, Ernesto; Musca, Francesco; Serravezza, Giuseppe; Mazzotta, Serena; Forcignano, Rc; Delena, M

doi:10.3892/ijo.6.1.65

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We included 33 RCTs to assess clinical effectiveness of the four drugs for treatment of NSCLC; three assessed docetaxel, 14 17-19 six gemcitabine, 13 20-27 six paclitaxel, 28-33 13 vinorelbine, [34][35][36][37][38][39][40][41][42][43][44][45][46] and five combined treatments. [47][48][49][50][51] The characteristics of these studies are presented in table 1.…”

Section: Resultsmentioning

confidence: 99%

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review

Clegg

2002

Thorax

View full text Add to dashboard Cite

Background: Lung cancer remains a devastating disease with few effective treatment options. Recent developments in chemotherapy have led to cautious optimism. This paper reviews the evidence on the clinical and cost effectiveness of four of the new generation drugs for patients with lung cancer. Methods: A systematic review of randomised controlled trials (RCTs) identified from 11 electronic databases (including Medline, Cochrane library and Embase), reference lists and contact with experts and industry was performed to assess clinical effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine. Clinical effectiveness was assessed using the outcomes of patient survival, quality of life, and adverse effects. Cost effectiveness was assessed by development of a costing model and presented as incremental cost per life year saved (LYS) compared with best supportive care (BSC). Results: Of the 33 RCTs included, five were judged to be of good quality, 10 of adequate quality, and 18 of poor quality. Gemcitabine, paclitaxel, and vinorelbine as first line treatment and docetaxel as second line treatment appear to be more beneficial for non-small cell lung cancer than BSC and older chemotherapy agents, increasing patient survival by 2-4 months against BSC and some comparator regimes. These gains in survival do not appear to be at the expense of quality of life. Survival gains were delivered at reasonable levels of incremental cost effectiveness for vinorelbine, vinorelbine with cisplatin, gemcitabine, gemcitabine with cisplatin, and paclitaxel with cisplatin regimens compared with BSC. Conclusion: Although the clinical benefits of the new drugs appear relatively small, their benefit to patients with lung cancer appears to be worthwhile and cost effective.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review

Clegg

2002

Thorax

View full text Add to dashboard Cite

show abstract

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

Delbaldo

Michiels

Syz³

et al. 2004

JAMA

322

169

View full text Add to dashboard Cite

Vinorelbine in Advanced Non???Small Cell Lung Cancer

Coukell¹,

Noble²,

Faulds³

1999

PharmacoEconomics

View full text Add to dashboard Cite

Although some limitations apply, the available data suggest that vinorelbine alone or in combination with cisplatin is cost saving compared with best supportive care for NSCLC, and that vinorelbine plus cisplatin is cost effective compared with some other combination regimens. The pharmacoeconomic placing of vinorelbine in relation to a number of other currently recommended first-line treatments for NSCLC has yet to be resolved, and data from ongoing multicentre phase III trials are awaited with interest. In the meantime, vinorelbine-based chemotherapy appears to be a suitable choice for first-line treatment of advanced NSCLC from both clinical and pharmacoeconomic perspectives.

show abstract

Results of a Clinical Multicentric Randomized Phase-Ii Study of Nonsmall Cell Lung-Cancer Treated With Vinorelbine Cisplatin Versus Vinorelbine Alone

Cited by 4 publications

References 0 publications

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

Vinorelbine in Advanced Non???Small Cell Lung Cancer

Contact Info

Product

Resources

About